Report of Foreign Issuer (6-k)
August 19 2020 - 4:34PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2020
Commission file number: 001-35223
BioLineRx Ltd.
(Translation of registrant’s name into English)
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
The Registrant announces that it will hold the 2020 Annual General Meeting of Shareholders on September 24, 2020 at 3:00 p.m. (Israel time) at the Registrant’s office, 2 HaMa’ayan Street, Modi’in, Israel.
Attached hereto as
Exhibit 1,
Exhibit 2 and
Exhibit 3, are, respectively, the Notice of Annual General Meeting and Proxy Statement, Proxy Card and Voting
Instruction Card for holders of American Depositary Shares.
This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
BioLineRx Ltd.
|
|
|
|
|
|
|
By:
|
/s/ Philip Serlin
|
|
|
|
Philip Serlin
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Apr 2023 to Apr 2024